Patents by Inventor Victor S. Gehling

Victor S. Gehling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20240116905
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Application
    Filed: April 28, 2023
    Publication date: April 11, 2024
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • LSD1 inhibitors and medical uses thereof
    Patent number: 11547695
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: April 27, 2021
    Date of Patent: January 10, 2023
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 11459315
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compostions thereof, which are useful for treating a variety of conditions associated with methyl modifying enzymes.
    Type: Grant
    Filed: November 8, 2018
    Date of Patent: October 4, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
  • CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE
    Publication number: 20220251073
    Abstract: The present disclosure relates to a crystalline Form 1 of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-di -methyl-N-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d] [1,3]dioxole-5-carboxamide, which is useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline form and methods of using said compositions in the treatment of various disorders.
    Type: Application
    Filed: July 23, 2020
    Publication date: August 11, 2022
    Inventors: Alamelu Banda, Victor S. Gehling
  • LSD1 INHIBITORS AND MEDICAL USES THEREOF
    Publication number: 20220079917
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: April 27, 2021
    Publication date: March 17, 2022
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 11274095
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Grant
    Filed: April 23, 2020
    Date of Patent: March 15, 2022
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • MODULATORS OF TREX1
    Publication number: 20220017502
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compositions thereof, which are useful for treating a variety of conditions associated with TREX1.
    Type: Application
    Filed: December 6, 2019
    Publication date: January 20, 2022
    Inventors: Anna Gardberg, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Jonathan E. Wilson, Kennedy Taveras
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20210230148
    Abstract: Provided are compounds of Formula (I): and pharmaceutically acceptable salts and compostions thereof, which are useful for treating a variety of conditions associated with methyl modifying enzymes.
    Type: Application
    Filed: November 8, 2018
    Publication date: July 29, 2021
    Inventors: Jehrod B. Brenneman, Alexandre Côté, Victor S. Gehling, Avinash Khanna, Julian R. Levell, Ludivine Moine
  • LSD1 inhibitors and medical uses thereof
    Patent number: 11013718
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 25, 2021
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20200317651
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Application
    Filed: April 23, 2020
    Publication date: October 8, 2020
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • LSD1 INHIBITORS AND MEDICAL USES THEREOF
    Publication number: 20200306223
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: November 1, 2019
    Publication date: October 1, 2020
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: 10689371
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 23, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
    Patent number: 10577350
    Abstract: The present disclosure relates to a crystalline Forms A, B, and C of (R)—N-((4-methoxy-6-methyl-2-oxo-1,2-di-hydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide, each of which are useful as modulators the activity of histone methyl modifying enzymes. The present disclosure also provides pharmaceutically acceptable compositions comprising the crystalline forms and methods of using said compositions in the treatment of various disorders.
    Type: Grant
    Filed: August 25, 2016
    Date of Patent: March 3, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, Alisha Arrigo, Donald Corson, Victor S. Gehling, Bruno Patrice Haché, Jean-Christophe Harmange, Jonathan Lane
  • LSD1 inhibitors and uses thereof
    Patent number: 10526287
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: January 7, 2020
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Côté, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Rishi G. Vaswani
  • LSD1 inhibitors and medical uses thereof
    Patent number: 10517849
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 31, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20190322651
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with methyl modifying enzymes. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with methyl modifying enzymes.
    Type: Application
    Filed: April 18, 2019
    Publication date: October 24, 2019
    Inventors: Alexandre Côté, Victor S. Gehling, Avinash Khanna, Ludivine Moine, Jacob I. Stuckey
  • LSD1 INHIBITORS AND MEDICAL USES THEREOF
    Publication number: 20190274998
    Abstract: Provided are novel compounds of Formula (I or Ia?): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions, associated with LSD1. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I or Ia?), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with LSD1.
    Type: Application
    Filed: October 26, 2017
    Publication date: September 12, 2019
    Applicant: Constellation Pharmaceuticals, Inc.
    Inventors: Francois Brucelle, Victor S. Gehling, Avinash Khanna
  • Therapeutic compounds and uses thereof
    Patent number: 10301253
    Abstract: Provided herein are compounds of formula I: and salts thereof and compositions and uses thereof. The compounds are useful as inhibitors of LSD1. Also included are pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various LSD1-mediated disorders.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 28, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, James Edmund Audia, Alexandre Cote, Martin Duplessis, Victor S. Gehling, Andrew Charles Good, Jean-Christophe Harmange, Yves LeBlanc, Christopher G. Nasveschuk, Alexander M. Taylor, Rishi G. Vaswani
  • MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
    Publication number: 20190125737
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Application
    Filed: May 31, 2018
    Publication date: May 2, 2019
    Inventors: Brian K. Albrecht, James Edmund Audia, Andrew Cook, Les A. Dakin, Martin Duplessis, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani
  • Modulators of methyl modifying enzymes, compositions and uses thereof
    Patent number: RE47428
    Abstract: Agents for modulating methyl modifying enzymes, compositions and uses thereof are provided herein.
    Type: Grant
    Filed: January 24, 2018
    Date of Patent: June 11, 2019
    Assignee: Constellation Pharmaceuticals, Inc.
    Inventors: Brian K. Albrecht, James Edmund Audia, Les A. Dakin, Victor S. Gehling, Jean-Christophe Harmange, Christopher G. Nasveschuk, Rishi G. Vaswani